Show that you understand the current state of research on your topic.
The length of a research proposal can vary quite a bit. A bachelor’s or master’s thesis proposal can be just a few pages, while proposals for PhD dissertations or research funding are usually much longer and more detailed. Your supervisor can help you determine the best length for your work.
One trick to get started is to think of your proposal’s structure as a shorter version of your thesis or dissertation , only without the results , conclusion and discussion sections.
Download our research proposal template
Writing a research proposal can be quite challenging, but a good starting point could be to look at some examples. We’ve included a few for you below.
Like your dissertation or thesis, the proposal will usually have a title page that includes:
The first part of your proposal is the initial pitch for your project. Make sure it succinctly explains what you want to do and why.
Your introduction should:
To guide your introduction , include information about:
As you get started, it’s important to demonstrate that you’re familiar with the most important research on your topic. A strong literature review shows your reader that your project has a solid foundation in existing knowledge or theory. It also shows that you’re not simply repeating what other people have already done or said, but rather using existing research as a jumping-off point for your own.
In this section, share exactly how your project will contribute to ongoing conversations in the field by:
Following the literature review, restate your main objectives . This brings the focus back to your own project. Next, your research design or methodology section will describe your overall approach, and the practical steps you will take to answer your research questions.
? or ? , , or research design? | |
, )? ? | |
, , , )? | |
? |
To finish your proposal on a strong note, explore the potential implications of your research for your field. Emphasise again what you aim to contribute and why it matters.
For example, your results might have implications for:
Last but not least, your research proposal must include correct citations for every source you have used, compiled in a reference list . To create citations quickly and easily, you can use our free APA citation generator .
Some institutions or funders require a detailed timeline of the project, asking you to forecast what you will do at each stage and how long it may take. While not always required, be sure to check the requirements of your project.
Here’s an example schedule to help you get started. You can also download a template at the button below.
Download our research schedule template
Research phase | Objectives | Deadline |
---|---|---|
1. Background research and literature review | 20th January | |
2. Research design planning | and data analysis methods | 13th February |
3. Data collection and preparation | with selected participants and code interviews | 24th March |
4. Data analysis | of interview transcripts | 22nd April |
5. Writing | 17th June | |
6. Revision | final work | 28th July |
If you are applying for research funding, chances are you will have to include a detailed budget. This shows your estimates of how much each part of your project will cost.
Make sure to check what type of costs the funding body will agree to cover. For each item, include:
To determine your budget, think about:
Once you’ve decided on your research objectives , you need to explain them in your paper, at the end of your problem statement.
Keep your research objectives clear and concise, and use appropriate verbs to accurately convey the work that you will carry out for each one.
I will compare …
A research aim is a broad statement indicating the general purpose of your research project. It should appear in your introduction at the end of your problem statement , before your research objectives.
Research objectives are more specific than your research aim. They indicate the specific ways you’ll address the overarching aim.
A PhD, which is short for philosophiae doctor (doctor of philosophy in Latin), is the highest university degree that can be obtained. In a PhD, students spend 3–5 years writing a dissertation , which aims to make a significant, original contribution to current knowledge.
A PhD is intended to prepare students for a career as a researcher, whether that be in academia, the public sector, or the private sector.
A master’s is a 1- or 2-year graduate degree that can prepare you for a variety of careers.
All master’s involve graduate-level coursework. Some are research-intensive and intend to prepare students for further study in a PhD; these usually require their students to write a master’s thesis . Others focus on professional training for a specific career.
Critical thinking refers to the ability to evaluate information and to be aware of biases or assumptions, including your own.
Like information literacy , it involves evaluating arguments, identifying and solving problems in an objective and systematic way, and clearly communicating your ideas.
If you want to cite this source, you can copy and paste the citation or click the ‘Cite this Scribbr article’ button to automatically add the citation to our free Reference Generator.
McCombes, S. & George, T. (2023, June 13). How to Write a Research Proposal | Examples & Templates. Scribbr. Retrieved 23 September 2024, from https://www.scribbr.co.uk/the-research-process/research-proposal-explained/
Other students also liked, what is a research methodology | steps & tips, what is a literature review | guide, template, & examples, how to write a results section | tips & examples.
An official website of the United States government
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
The PMC website is updating on October 15, 2024. Learn More or Try it out now .
Department of Anaesthesiology, Bangalore Medical College and Research Institute, Bengaluru, Karnataka, India
Writing the proposal of a research work in the present era is a challenging task due to the constantly evolving trends in the qualitative research design and the need to incorporate medical advances into the methodology. The proposal is a detailed plan or ‘blueprint’ for the intended study, and once it is completed, the research project should flow smoothly. Even today, many of the proposals at post-graduate evaluation committees and application proposals for funding are substandard. A search was conducted with keywords such as research proposal, writing proposal and qualitative using search engines, namely, PubMed and Google Scholar, and an attempt has been made to provide broad guidelines for writing a scientifically appropriate research proposal.
A clean, well-thought-out proposal forms the backbone for the research itself and hence becomes the most important step in the process of conduct of research.[ 1 ] The objective of preparing a research proposal would be to obtain approvals from various committees including ethics committee [details under ‘Research methodology II’ section [ Table 1 ] in this issue of IJA) and to request for grants. However, there are very few universally accepted guidelines for preparation of a good quality research proposal. A search was performed with keywords such as research proposal, funding, qualitative and writing proposals using search engines, namely, PubMed, Google Scholar and Scopus.
Five ‘C’s while writing a literature review
A proposal needs to show how your work fits into what is already known about the topic and what new paradigm will it add to the literature, while specifying the question that the research will answer, establishing its significance, and the implications of the answer.[ 2 ] The proposal must be capable of convincing the evaluation committee about the credibility, achievability, practicality and reproducibility (repeatability) of the research design.[ 3 ] Four categories of audience with different expectations may be present in the evaluation committees, namely academic colleagues, policy-makers, practitioners and lay audiences who evaluate the research proposal. Tips for preparation of a good research proposal include; ‘be practical, be persuasive, make broader links, aim for crystal clarity and plan before you write’. A researcher must be balanced, with a realistic understanding of what can be achieved. Being persuasive implies that researcher must be able to convince other researchers, research funding agencies, educational institutions and supervisors that the research is worth getting approval. The aim of the researcher should be clearly stated in simple language that describes the research in a way that non-specialists can comprehend, without use of jargons. The proposal must not only demonstrate that it is based on an intelligent understanding of the existing literature but also show that the writer has thought about the time needed to conduct each stage of the research.[ 4 , 5 ]
The contents or formats of a research proposal vary depending on the requirements of evaluation committee and are generally provided by the evaluation committee or the institution.
In general, a cover page should contain the (i) title of the proposal, (ii) name and affiliation of the researcher (principal investigator) and co-investigators, (iii) institutional affiliation (degree of the investigator and the name of institution where the study will be performed), details of contact such as phone numbers, E-mail id's and lines for signatures of investigators.
The main contents of the proposal may be presented under the following headings: (i) introduction, (ii) review of literature, (iii) aims and objectives, (iv) research design and methods, (v) ethical considerations, (vi) budget, (vii) appendices and (viii) citations.[ 4 ]
It is also sometimes termed as ‘need for study’ or ‘abstract’. Introduction is an initial pitch of an idea; it sets the scene and puts the research in context.[ 6 ] The introduction should be designed to create interest in the reader about the topic and proposal. It should convey to the reader, what you want to do, what necessitates the study and your passion for the topic.[ 7 ] Some questions that can be used to assess the significance of the study are: (i) Who has an interest in the domain of inquiry? (ii) What do we already know about the topic? (iii) What has not been answered adequately in previous research and practice? (iv) How will this research add to knowledge, practice and policy in this area? Some of the evaluation committees, expect the last two questions, elaborated under a separate heading of ‘background and significance’.[ 8 ] Introduction should also contain the hypothesis behind the research design. If hypothesis cannot be constructed, the line of inquiry to be used in the research must be indicated.
It refers to all sources of scientific evidence pertaining to the topic in interest. In the present era of digitalisation and easy accessibility, there is an enormous amount of relevant data available, making it a challenge for the researcher to include all of it in his/her review.[ 9 ] It is crucial to structure this section intelligently so that the reader can grasp the argument related to your study in relation to that of other researchers, while still demonstrating to your readers that your work is original and innovative. It is preferable to summarise each article in a paragraph, highlighting the details pertinent to the topic of interest. The progression of review can move from the more general to the more focused studies, or a historical progression can be used to develop the story, without making it exhaustive.[ 1 ] Literature should include supporting data, disagreements and controversies. Five ‘C's may be kept in mind while writing a literature review[ 10 ] [ Table 1 ].
The research purpose (or goal or aim) gives a broad indication of what the researcher wishes to achieve in the research. The hypothesis to be tested can be the aim of the study. The objectives related to parameters or tools used to achieve the aim are generally categorised as primary and secondary objectives.
The objective here is to convince the reader that the overall research design and methods of analysis will correctly address the research problem and to impress upon the reader that the methodology/sources chosen are appropriate for the specific topic. It should be unmistakably tied to the specific aims of your study.
In this section, the methods and sources used to conduct the research must be discussed, including specific references to sites, databases, key texts or authors that will be indispensable to the project. There should be specific mention about the methodological approaches to be undertaken to gather information, about the techniques to be used to analyse it and about the tests of external validity to which researcher is committed.[ 10 , 11 ]
The components of this section include the following:[ 4 ]
Population refers to all the elements (individuals, objects or substances) that meet certain criteria for inclusion in a given universe,[ 12 ] and sample refers to subset of population which meets the inclusion criteria for enrolment into the study. The inclusion and exclusion criteria should be clearly defined. The details pertaining to sample size are discussed in the article “Sample size calculation: Basic priniciples” published in this issue of IJA.
The researcher is expected to give a detailed account of the methodology adopted for collection of data, which include the time frame required for the research. The methodology should be tested for its validity and ensure that, in pursuit of achieving the results, the participant's life is not jeopardised. The author should anticipate and acknowledge any potential barrier and pitfall in carrying out the research design and explain plans to address them, thereby avoiding lacunae due to incomplete data collection. If the researcher is planning to acquire data through interviews or questionnaires, copy of the questions used for the same should be attached as an annexure with the proposal.
This addresses the strength of the research with respect to its neutrality, consistency and applicability. Rigor must be reflected throughout the proposal.
It refers to the robustness of a research method against bias. The author should convey the measures taken to avoid bias, viz. blinding and randomisation, in an elaborate way, thus ensuring that the result obtained from the adopted method is purely as chance and not influenced by other confounding variables.
Consistency considers whether the findings will be consistent if the inquiry was replicated with the same participants and in a similar context. This can be achieved by adopting standard and universally accepted methods and scales.
Applicability refers to the degree to which the findings can be applied to different contexts and groups.[ 13 ]
This section deals with the reduction and reconstruction of data and its analysis including sample size calculation. The researcher is expected to explain the steps adopted for coding and sorting the data obtained. Various tests to be used to analyse the data for its robustness, significance should be clearly stated. Author should also mention the names of statistician and suitable software which will be used in due course of data analysis and their contribution to data analysis and sample calculation.[ 9 ]
Medical research introduces special moral and ethical problems that are not usually encountered by other researchers during data collection, and hence, the researcher should take special care in ensuring that ethical standards are met. Ethical considerations refer to the protection of the participants' rights (right to self-determination, right to privacy, right to autonomy and confidentiality, right to fair treatment and right to protection from discomfort and harm), obtaining informed consent and the institutional review process (ethical approval). The researcher needs to provide adequate information on each of these aspects.
Informed consent needs to be obtained from the participants (details discussed in further chapters), as well as the research site and the relevant authorities.
When the researcher prepares a research budget, he/she should predict and cost all aspects of the research and then add an additional allowance for unpredictable disasters, delays and rising costs. All items in the budget should be justified.
Appendices are documents that support the proposal and application. The appendices will be specific for each proposal but documents that are usually required include informed consent form, supporting documents, questionnaires, measurement tools and patient information of the study in layman's language.
As with any scholarly research paper, you must cite the sources you used in composing your proposal. Although the words ‘references and bibliography’ are different, they are used interchangeably. It refers to all references cited in the research proposal.
Successful, qualitative research proposals should communicate the researcher's knowledge of the field and method and convey the emergent nature of the qualitative design. The proposal should follow a discernible logic from the introduction to presentation of the appendices.
Conflicts of interest.
There are no conflicts of interest.
Basic features of a proposal.
There are some basic features that all proposals are likely to contain, which are summarised in the table below (based on information in Björk, Björk & Räisänen, 1996). However, the information provided is only a guideline – you may need to adjust according to your document’s purpose and your discipline’s preferences.
Academic Proposals
An academic proposal, such as an application for PhD studies, usually looks a bit different from a business proposal. The following sections are commonly found in an academic proposal:
You will find information on all the sections here: The Elements of a Proposal by Frank Pajares
N.B. Information regarding features of other proposal types will be available here in the future.
Reference : Björk,L., Björk, M. & C. Räisänen (1996). Academic Writing, A University Writing Course . Studentlitteratur.
Inclusion across the lifespan in human subjects research.
Learn about the Inclusion Across the Lifespan policy and how to comply with this policy in applications and progress reports. All human subjects research supported by NIH must include participants of all ages, including children and older adults, unless there are scientific or ethical reasons not to include them.
The purpose of the Inclusion Across the Lifespan Policy is to ensure individuals are included in clinical research in a manner appropriate to the scientific question under study so that the knowledge gained from NIH-funded research is applicable to all those affected by the researched diseases/conditions. The policy expands the Inclusion of Children in Clinical Research Policy to include individuals of all ages, including children and older adults . The policy also requires that the age at enrollment of each participant be collected in progress reports.
The Inclusion Across the Lifespan policy is now in effect, and applies to all grant applications submitted for due dates on or after January 25, 2019 . The policy also applies to solicitations for Research & Development contracts issued January 25, 2019 or later, and intramural studies submitted on/after this date. Ongoing, non-competing awards will be expected to comply with the policy at the submission of a competing renewal application. Research that was submitted before January 25, 2019 continues to be subject to the Inclusion of Children in Clinical Research Policy .
Applications and proposals involving human subjects research must address plans for including individuals across the lifespan in the PHS Human Subjects and Clinical Trial Information Form. Any age-related exclusions must include a rationale and justification based on a scientific or ethical basis. Refer to the PHS Human Subjects and Clinical Trial Information Form Instructions for complete guidance on what to address.
Scientific Review Groups will assess each application/proposal as being "acceptable" or "unacceptable" with regard to the age-appropriate inclusion or exclusion of individuals in the research project. For additional information on review considerations, refer to the Guidelines for the Review of Inclusion in Clinical Research . For information regarding the coding used to rate inclusion during peer review, see the list of NIH Peer Review Inclusion Codes .
NIH recipients/offerors must submit individual-level data on participant age at enrollment in progress reports. Age at enrollment must be provided along with information on sex or gender, race, and ethnicity in the Inclusion Enrollment Report. Units for reporting age at enrollment range from minutes to years.
: NIH Policy and Guidelines on the Inclusion of Individuals Across the Lifespan as Participants in Research Involving Human Subjects | This policy revises previous policy and guidelines regarding the inclusion of children in research. Changes to the policy include (1) the applicability of the policy to individuals of all ages, (2) clarification of potentially acceptable reasons for excluding participants on age, and (3) a requirement to provide data on participant age at enrollment in progress reports. | December 19, 2017 |
: Inclusion of Children in Clinical Research: Change in NIH Definition | For the purposes of inclusion policy, a child is defined as individuals under 18 years old. Applicants/offerors for NIH funding are still expected to justify the age range of the proposed participants in their clinical research. | October 13, 2015 |
NIH Policy and Guidelines on The Inclusion of Children as Participants in Research Involving Human Subjects | The goal of this policy is to increase the participation of children in research so that adequate data will be developed to support the treatment modalities for disorders and conditions that affect adults and may also affect children. | March 6, 1998 |
Infographic that walks through the elements of the existing dataset or resource definition to help users understand whether how it applies to their research. | August 2, 2024 | |
Report on the representation of participants in human subjects studies from fiscal years 2018-2021 for FY2018 projects associated with the listed Research, Condition, and Disease Categorization (RCDC) categories. | October 31, 2023 | |
This document describes several mock studies as examples of how to consider the Inclusion Across the Lifespan policy in study design and eligibility criteria. Examples include commentary on scientific and ethical reasons that may be acceptable or unacceptable for age-based exclusion. | September 09, 2023 | |
This one-page resource highlights allowable costs for NIH grants that can be utilized to enhance inclusion through recruitment and retention activities. Allowable costs listed in the NIH Grants Policy Statement are provided with examples of inclusion-related activities. | August 10, 2023 | |
April 20, 2022 | ||
NIH’s Inclusion Policy Officer Dawn Corbett covers inclusion plans during peer review and post-award in Part 2 of this NIH All About Grants podcast miniseries. | April 20, 2022 | |
Using the Participant-level Data Template | For research that falls under the Inclusion Across the Lifespan policy, submission of individual-level data is required in progress reports. This tip sheet serves as a quick guide for using the participant-level data template in the Human Subjects System to populate data in the cumulative (actual) enrollment table. | January 20, 2022 |
: Recruitment and Retention | Document listing resources on recruitment and retention of women, racial and ethnic minorities, and individuals across the lifespan. Resources include toolkits, articles, and more. | May 9, 2022 |
: Including Diverse Populations in NIH-funded Clinical Research | Video presentation by the NIH Inclusion Policy Officer for the NIH Grants Conference PreCon event, Human Subjects Research: Policies, Clinical Trials, & Inclusion, in December 2022. The presentation explains NIH inclusion policies and requirements for applicants and recipients. | January 27, 2023 |
- (PDF - 1.1 MB) | Report summarizing the presentations and discussions that took place during the Inclusion Across the Lifespan II Workshop on September 2, 2020. | December 10, 2020 |
: Some Thoughts Following the NIH Inclusion Across the Lifespan II Workshop | Blog post by NIH's Deputy Director of Extramural Research, Dr. Mike Lauer, highlighting the Inclusion Across the Lifespan II Workshop. | December 10, 2020 |
Entering Inclusion Data Using the Participant Level Data Template | This video tutorial demonstrates how to enter inclusion data using the Participant Level Data Template in the Human Subjects System (HSS). | February 26, 2020 |
Guidance for Applying the Inclusion Across the Lifespan Policy | At-a-glance guidance for complying with the policy in applications and progress reports. | May 3, 2019 |
The Inclusion Across the Lifespan Policy | The "All About Grants" podcast featuring an interview with the NIH Inclusion Policy Officer about the Inclusion Across the Lifespan policy. | August 27, 2018 |
HSS overview and training information | As of June 9, 2018, the Human Subjects System (HSS) replaced the Inclusion Management System (IMS). Similar to IMS, HSS is used by NIH staff, grant applicants, and recipients to manage human subjects information, including inclusion information. | May 25, 2018 |
The Inclusion Across the Lifespan Policy | Blog post by Dr. Mike Lauer, Deputy Director of Extramural Research, and Dawn Corbett, NIH Inclusion Policy Officer, titled Understanding Age in the NIH Portfolio: Implementation of the NIH Inclusion Across the Lifespan Policy | November 13, 2018 |
Inclusion Across the Lifespan | Summary report from the Inclusion Across the Lifespan workshop held June 1-2, 2017 | July, 2017 |
DHSR One pager of resources for external users
Have additional questions? Contact your program officer or the Inclusion policy team: [email protected]
Antibody-drug conjugates (ADCs) have become a pivotal area in the research and development of antitumor drugs. They provide innovative possibilities for tumor therapy by integrating the tumor-targeting capabilities of monoclonal antibodies with the cytotoxic effect of small molecule drugs. Pharmacometrics, an important discipline, facilitates comprehensive understanding of the pharmacokinetic characteristics of ADCs by integrating clinical trial data through modeling and simulation. However, due to the complex structure of ADCs, their modeling approaches are still unclear. In this review, we analyzed published population pharmacokinetic models for ADCs and classified them into single-analyte, two-analyte, and three-analyte models. We also described the benefits, limitations, and recommendations for each model. Furthermore, we suggested that the development of population pharmacokinetic models for ADCs should be rigorously considered and established based on four key aspects: (1) research objectives; (2) available in vitro and animal data; (3) accessible clinical information; and (4) the capability of bioanalytical methods. This review offered insights to guide the application of pharmacometrics in the clinical research of ADCs, thereby contributing to more effective therapeutic development.
This is a preview of subscription content, log in via an institution to check access.
Subscribe and save.
Price includes VAT (Russian Federation)
Instant access to the full article PDF.
Rent this article via DeepDyve
Institutional subscriptions
Figure from Gupta et al. [ 14 ], under CCC license
Figure from Garrett et al. [ 11 ], under CC BY 4.0 license
Figure from Li et al. [ 20 ], under CC BY-NC 4.0 license.
Figure from Chudasama et al. [ 22 ], under CCC license.
Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641–61. https://doi.org/10.1038/s41573-023-00709-2 .
Article CAS PubMed Google Scholar
Deslandes A. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs. 2014;6(4):859–70. https://doi.org/10.4161/mabs.28965 .
Article PubMed PubMed Central Google Scholar
Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https://doi.org/10.1038/s41392-022-00947-7 .
Article CAS PubMed PubMed Central Google Scholar
Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;29(9):2354–66. https://doi.org/10.1007/s11095-012-0800-y .
Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063–70. https://doi.org/10.1158/1078-0432.CCR-04-0789 .
Singh AP, Shin YG, Shah DK. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm Res. 2015;32(11):3508–25. https://doi.org/10.1007/s11095-015-1626-1 .
Marshall SF, Burghaus R, Cosson V, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol. 2016;5(3):93–122. https://doi.org/10.1002/psp4.12049 .
Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60. https://doi.org/10.1182/blood-2013-01-466706 .
Fostvedt LK, Hibma JE, Masters JC, Vandendries E, Ruiz-Garcia A. Pharmacokinetic/pharmacodynamic modeling to support the re-approval of gemtuzumab ozogamicin. Clin Pharmacol Ther. 2019;106(5):1006–17. https://doi.org/10.1002/cpt.1500 .
Zuo P. Capturing the magic bullet: pharmacokinetic principles and modeling of antibody-drug conjugates. AAPS J. 2020;22(5):105. https://doi.org/10.1208/s12248-020-00475-8 .
Garrett M, Ruiz-Garcia A, Parivar K, et al. Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46(3):211–22. https://doi.org/10.1007/s10928-018-9614-9 .
Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90. https://doi.org/10.1158/0008-5472.CAN-08-1776 .
Center for Drug Evaluation and Research (CDR). Clinical pharmacology and biopharmaceutics review for trastuzumab emtansine. Application number: 125427Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/125427Orig1s000ClinPharmR.pdf . Accessed 20 Apr 2024.
Gupta M, Lorusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012;52(5):691–703. https://doi.org/10.1177/0091270011403742 .
DiJoseph JF, Dougher MM, Kalyandrug LB, et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin Cancer Res. 2006;12(1):242–9. https://doi.org/10.1158/1078-0432.CCR-05-1905 .
Scott LJ. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma. Drugs. 2017;77(4):435–45. https://doi.org/10.1007/s40265-017-0705-5 .
Center for Drug Evaluation and Research (CDR). Clinical pharmacology and biopharmaceutics review for brentuximab vedotin. Application number: 125388Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125388Orig1s000ClinPharmR.pdf . Accessed 20 Apr 2024.
Suri A, Mould DR, Liu Y, Jang G, Venkatakrishnan K. Population PK and exposure-response relationships for the antibody-drug conjugate brentuximab vedotin in CTCL patients in the phase III ALCANZA study. Clin Pharmacol Ther. 2018;104(5):989–99. https://doi.org/10.1002/cpt.1037 .
Suri A, Mould DR, Song G, et al. Population pharmacokinetic modeling and exposure-response assessment for the antibody-drug conjugate brentuximab vedotin in Hodgkin’s lymphoma in the phase III ECHELON-1 study. Clin Pharmacol Ther. 2019;106(6):1268–79. https://doi.org/10.1002/cpt.1530 .
Li H, Han TH, Hunder NN, Jang G, Zhao B. Population pharmacokinetics of brentuximab vedotin in patients with CD30-expressing hematologic malignancies. J Clin Pharmacol. 2017;57(9):1148–58. https://doi.org/10.1002/jcph.920 .
Lu D, Joshi A, Wang B, et al. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet. 2013;52(8):657–72. https://doi.org/10.1007/s40262-013-0060-y .
Chudasama VL, Schaedeli Stark F, Harrold JM, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther. 2012;92(4):520–7. https://doi.org/10.1038/clpt.2012.153 .
Dornan D, Bennett F, Chen Y, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114(13):2721–9. https://doi.org/10.1182/blood-2009-02-205500 .
Center for Drug Evaluation and Research (CDR). Clinical pharmacology review for polatuzumab vedotin. Application number: 761121Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761121Orig1s000ClinPharmR.pdf . Accessed 20 Apr 2024.
Lu D, Lu T, Gibiansky L, Li X, Li C, Agarwal P, Shemesh CS, Shi R, Dere RC, Hirata J, Miles D, Chanu P, Girish S, Jin JY. Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. CPT Pharmacometrics Syst Pharmacol. 2020;9(1):48–59. https://doi.org/10.1002/psp4.12482 .
Breij EC, de Goeij BE, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74(4):1214–26. https://doi.org/10.1158/0008-5472.CAN-13-2440 .
Center for Drug Evaluation and Research (CDR). Muti-discipline review for tisotumab vedotin. Application number: 761208Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761208Orig1s000MultidisciplineR.pdf . Accessed 20 Apr 2024.
Gibiansky L, Passey C, Voellinger J, et al. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors. CPT Pharmacometrics Syst Pharmacol. 2022;11(10):1358–70. https://doi.org/10.1002/psp4.12850 .
Passey C, Voellinger J, Gibiansky L, et al. Exposure-safety and exposure-efficacy analyses for tisotumab vedotin for patients with locally advanced or metastatic solid tumors. CPT Pharmacometrics Syst Pharmacol. 2023;12(9):1262–73. https://doi.org/10.1002/psp4.13007 .
Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–38. https://doi.org/10.1182/blood-2013-10-535088 .
Rathi C, Collins J, Struemper H, et al. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):851–63. https://doi.org/10.1002/psp4.12660 .
Collins J, van Noort M, Rathi C, et al. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2023;12(10):1411–24. https://doi.org/10.1002/psp4.1301 .
Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094–105. https://doi.org/10.1182/blood-2017-10-813493 .
CDR. Center for drug evaluation and research. Muti-discipline review for loncastuximab tesirine. Application number: 761196Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761196Orig1s000MultidisciplineR.pdf . Accessed 20 Apr 2024.
Hess B, Townsend W, Ai W, et al. Efficacy and safety exposure-response analysis of loncastuximab tesirine in patients with B cell non-Hodgkin lymphoma. AAPS J. 2021;24(1):11. https://doi.org/10.1208/s12248-021-00660-3 .
Kamath AV, Iyer S. Preclinical pharmacokinetic considerations for the development of antibody drug conjugates. Pharm Res. 2015;32(11):3470–9. https://doi.org/10.1007/s11095-014-1584-z .
Xu K, Liu L, Saad OM, et al. Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry. Anal Biochem. 2011;412(1):56–66. https://doi.org/10.1016/j.ab.2011.01.004 .
Center for Drug Evaluation and Research (CDR). Clinical Pharmacology Considerations for Antibody-Drug Conjugates, Guide for industry. 2024. Available at: https://www.fda.gov/media/155997/download . Accessed 20 Apr 2024.
National Medical Products Administration. Technical guidelines for clinical development of anti-cancer antibody-drug conjugates. 2023. Available at: https://www.cde.org.cn/zdyz/downloadAtt?idCODE=65c496c5321ca27252149c11496a6a53 . Accessed 20 Apr 2024.
Sukumaran S, Zhang C, Leipold DD, et al. Development and translational application of an integrated, mechanistic model of antibody-drug conjugate pharmacokinetics. AAPS J. 2017;19(1):130–40. https://doi.org/10.1208/s12248-016-9993-z .
Chen Y, Samineni D, Mukadam S, et al. Physiologically based pharmacokinetic modeling as a tool to predict drug interaction for antibody-drug conjugates. Clin Pharmacokinet. 2015;54(1):81–93. https://doi.org/10.1007/s40262-014-0182-x .
Samineni D, Ding H, Ma F, et al. Physiologically based pharmacokinetic model-informed drug development for polatuzumab vedotin: label for drug-drug interactions without dedicated clinical trials. J Clin Pharmacol. 2020;60(Suppl 1):S120–31. https://doi.org/10.1002/jcph.1718 .
Liu SN, Li C. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. Cancer Chemother Pharmacol. 2021;87(6):743–65. https://doi.org/10.1007/s00280-021-04250-0 .
Download references
The authors thank all the contributors for their invaluable contributions to this review.
Authors and affiliations.
State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
Xiuqi Li, Shupeng Liu, Mengyang Yu, Xiaofei Wu & Hongyun Wang
College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China
You can also search for this author in PubMed Google Scholar
Correspondence to Hongyun Wang .
Conflicts of interest.
Xiuqi Li, Dan Liu, Shupeng Liu, Mengyang Yu, Xiaofei Wu, and Hongyun Wang declare they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This research was supported by National High Level Hospital Clinical Research Funding (2022-PUMCH-B-118).
XL: Investigation, visualization, writing—original draft. DL: Investigation, data curation. SL: Data curation, formal analysis. MY, XW: Valildation and methodology. HW: Writing—review and editing, supervision, funding acquisition, conceptualization.
Data availability is not applicable to this article as no new data were created or analyzed in this study.
Not applicable.
Consent for publication, code availability, rights and permissions.
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
Li, X., Liu, D., Liu, S. et al. Application of Pharmacometrics in Advancing the Clinical Research of Antibody-Drug Conjugates: Principles and Modeling Strategies. Clin Pharmacokinet (2024). https://doi.org/10.1007/s40262-024-01423-x
Download citation
Accepted : 03 September 2024
Published : 26 September 2024
DOI : https://doi.org/10.1007/s40262-024-01423-x
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
COMMENTS
Characteristics of a Successful Research Proposal . A successful research proposal: 1. Is innovative 2. Includes specific aims 3. Includes preliminary data 4. Describes approach 5. Indicates the significance of the proposal with regard to the specific award and conveys its impact on science and your personal growth.
The purpose of this article is to take students through a step-by-step process of writing good research proposals by discussing the essential ingredients of a good research proposal. ... and hypotheses as well as their distinguishing characteristics; (c) demonstrate a good understanding of the relevant elements to be considered in the ...
Cohesive ties. Cohesive ties are linguistic devices that link words, phrases and clauses into fluent sentences and paragraphs. These are important in a research proposal as they help you signpost and order your material. They are especially useful in the methodology section to ensure that your process is clearly and logically set out.
So in this guide, we'll outline all the elements of a good research proposal and explain why they're important. The elements of a good research proposal are the title, the introduction, literature review, aims and objectives, methodology, scope of the research, outline and timetable, and bibliography. It's important to include these ...
Research proposal examples. Writing a research proposal can be quite challenging, but a good starting point could be to look at some examples. We've included a few for you below. Example research proposal #1: "A Conceptual Framework for Scheduling Constraint Management".
Literature Review. This key component of the research proposal is the most time-consuming aspect in the preparation of your research proposal. As described in Chapter 5, the literature review provides the background to your study and demonstrates the significance of the proposed research.Specifically, it is a review and synthesis of prior research that is related to the problem you are setting ...
The main purpose of a scientific research proposal is to convince your audience that your project is worthwhile, and that you have the expertise and wherewithal to complete it. The elements of an effective research proposal mirror those of the research process itself, which we'll outline below. Essentially, the research proposal should ...
Research proposal formats vary depending on the size of the planned research, the number of participants, the discipline, the characteristics of the research, etc. The following outline assumes an individual researcher. This is just a SAMPLE; several other ways are equally good and can be successful.
Chapter 4 pp. 76-82: The Insider's Guide to Grantmaking How Foundations Find, Fund, and Manage Effective Programs. Proposals come in all shapes, lengths, and sizes; as program officer, you can review them according to any number of criteria. Nonetheless, it is possible to identify some generic characteristics that are hallmarks of a good ...
It puts the proposal in context. 3. The introduction typically begins with a statement of the research problem in precise and clear terms. 1. The importance of the statement of the research problem 5: The statement of the problem is the essential basis for the construction of a research proposal (research objectives, hypotheses, methodology ...
The title of your proposal may be different from the title of your final research project, but that is completely normal! Your findings may help you come up with a title that is more fitting for the final project. Characteristics of good proposal titles are (Al-Riyami, 2008): Catchy: It catches the reader's attention by peaking their interest.
INTRODUCTION. Scientific research is usually initiated by posing evidenced-based research questions which are then explicitly restated as hypotheses.1,2 The hypotheses provide directions to guide the study, solutions, explanations, and expected results.3,4 Both research questions and hypotheses are essentially formulated based on conventional theories and real-world processes, which allow the ...
Your proposal must be carefully planned and complete. It must be relevant and significant. It must be beneficial and effective. To accomplish those tasks, carefully and concisely answer the following questions in your proposal. Then complement that content with clear, effective writing to win over your reviewers.
Characteristics of a good . research proposal . 1. Adequate background information: ... In the preparation of an effective research proposal in library and information science, a researcher needs ...
characteristics; (c) demonstrate a good understanding of the relevant elements to be considered in the constituent sections of a good research proposal; and (d) comprehend the elements of a research proposal that should feature in the final written ... ter, find it difficult to write good research proposals. Thus, there is the need to explain ...
An interactive workshop on 'The Critical Steps for Successful Research: The Research Proposal and Scientific Writing' was conducted in conjunction with the 64 th Annual Conference of the Indian Pharmaceutical Congress-2012 at Chennai, India. In essence, research is performed to enlighten our understanding of a contemporary issue relevant to the needs of society.
This section of the proposal must provide a broad overview of the topic. The jargon and key terms used in the particular topic must also be thoroughly explained in order to avoid confusion. The interest of the researcher in the particular topic must also be clearly outlined while at the same time mentioning, albeit briefly at this point, a critical review of the main literature that covers the ...
Proposal Characteristics. 1. The need for the proposed activity is clearly established, preferably with data. 2. The most important ideas are highlighted and repeated in several places. 3. Appropriate detail is provided in all portions of the proposal such as in the objectives and a detailed schedule of activities for the project or project ...
A good research question is essential to guide your research paper, dissertation, or thesis. All research questions should be: Focused on a single problem or issue. Researchable using primary and/or secondary sources. Feasible to answer within the timeframe and practical constraints. Specific enough to answer thoroughly.
Characteristics of a good research question. The first step in a literature search is to construct a well-defined question. This helps in ensuring a comprehensive and efficient search of the available literature for relevant publications on your topic. The well-constructed research question provides guidance for determining search terms and ...
Research proposal examples. Writing a research proposal can be quite challenging, but a good starting point could be to look at some examples. We've included a few for you below. Example research proposal #1: 'A Conceptual Framework for Scheduling Constraint Management'.
A proposal needs to show how your work fits into what is already known about the topic and what new paradigm will it add to the literature, while specifying the question that the research will answer, establishing its significance, and the implications of the answer. [2] The proposal must be capable of convincing the evaluation committee about ...
acceptance or refutation each alternative solution. 4. An evaluation of the benefits of your proposal. positive effects of your proposal, for example, cost benefits or sustainability. 5. Possible counter arguments to your proposal. an awareness of possible objections to your proposal that you, in turn, argue against. 6.
Research that was submitted before January 25, 2019 continues to be subject to the Inclusion of Children in Clinical Research Policy. Applications & Proposals. Applications and proposals involving human subjects research must address plans for including individuals across the lifespan in the PHS Human Subjects and Clinical Trial Information Form.
Antibody-drug conjugates (ADCs) have become a pivotal area in the research and development of antitumor drugs. They provide innovative possibilities for tumor therapy by integrating the tumor-targeting capabilities of monoclonal antibodies with the cytotoxic effect of small molecule drugs. Pharmacometrics, an important discipline, facilitates comprehensive understanding of the pharmacokinetic ...